Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Concizumab

Generic Name: Concizumab

Drug Type: Biotech

CAS Number: 1312299-39-0

Unique Ingredient Identifier: 68603V9EAF

Overview

Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.

Background

Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Not yet recruiting

Posted: 2025/02/18

Sponsor:Novo Nordisk A/S

ID:NCT06831734

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Posted: 2024/02/29

Sponsor:Novo Nordisk A/S

ID:NCT06285071

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Phase 3

Recruiting

Posted: 2021/11/26

Sponsor:Novo Nordisk A/S

ID:NCT05135559

Compassionate Use of Concizumab if You Have Haemophilia

Posted: 2021/06/10

Sponsor:Novo Nordisk A/S

ID:NCT04921956

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Phase 3

Active, not recruiting

Posted: 2019/09/10

Sponsor:Novo Nordisk A/S

ID:NCT04083781

FDA Approved Products

Alhemo

Manufacturer:Novo Nordisk

Route:SUBCUTANEOUS

Strength:40 mg in 1 mL

Approved: 2024/12/10

NDC:0169-2084

Alhemo

Manufacturer:Novo Nordisk

Route:SUBCUTANEOUS

Strength:100 mg in 1 mL

Approved: 2024/12/10

NDC:0169-2081

Alhemo

Manufacturer:Novo Nordisk

Route:SUBCUTANEOUS

Strength:100 mg in 1 mL

Approved: 2024/12/10

NDC:0169-2080

Singapore Approved Products

No Singapore products found for this drug

Related News

Novo Nordisk's Once-Weekly Sogroya Shows Efficacy in Children with Growth Disorders in Phase 3 Trial

12 days ago

The REAL8 phase 3 trial demonstrated that once-weekly Sogroya (somapacitan) was non-inferior to daily growth hormone in children with growth disorders, with superior results in Noonan syndrome patients.

CDMO Market Report: Key Regulatory Approvals and Clinical Advances in March-April 2025

a month ago

Multiple CDMOs secured significant contract manufacturing opportunities as regulatory bodies approved new indications for established drugs, particularly in oncology and rare diseases.

Congress's Failure to Renew Priority Review Voucher Program Threatens Rare Disease Drug Development

3 months ago

The FDA's rare pediatric disease Priority Review Voucher program expired in December 2023, despite unanimous congressional support for renewal, leaving biotech companies unable to receive new vouchers worth approximately $150 million.

Fitusiran Shows Promise in Reducing Bleeding Episodes in Hemophilia A and B Patients

4 months ago

Fitusiran, an RNA interference therapy, is highlighted as a potential breakthrough for hemophilia A and B treatment, regardless of inhibitor status.

Hemgenix Gene Therapy Shows Sustained Efficacy in Hemophilia B Patients After Four Years

4 months ago

Data from the HOPE-B trial demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) provides long-term bleed protection for adults with hemophilia B.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy